A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Tralokinumab Monotherapy in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) Who Are Candidates for Systemic Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 6
- Sponsors LEO Pharma
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2019 Planned End Date changed from 18 Jun 2020 to 20 Feb 2021.
- 09 Sep 2019 Planned primary completion date changed from 4 Jul 2019 to 20 Apr 2020.